This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: Fujifilm Corporation. Active years: 2015-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2018
Title: Yukari Kanzaki: Innovator in Monoclonal Antibody Development
Introduction
Yukari Kanzaki is a prominent inventor based in Minato-ku, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, her work focuses on biomarkers that are crucial for the detection and diagnosis of various carcinomas and necrosis.
Latest Patents
Kanzaki's latest patents include innovative monoclonal antibodies targeting necrosis markers. One of her notable patents is for a monoclonal antibody against the necrosis marker PRDX4. This invention aims to provide a highly specific biomarker that can be effectively utilized in the detection and diagnosis of various lesions related to different types of carcinomas. The patent describes a monoclonal antibody consisting of a specific amino acid sequence or variations thereof that maintain the same functional properties.
Another significant patent involves a monoclonal antibody against the necrosis marker ERP29. Similar to her previous work, this invention addresses the need for a biomarker with high specificity for effective detection and diagnosis of lesions associated with carcinomas and necrosis. The patent outlines the amino acid sequences involved and their functional equivalence.
Career Highlights
Kanzaki is currently employed at Fujifilm Corporation, where she continues to advance her research in biotechnology. Her work has garnered attention for its potential applications in medical diagnostics and therapeutic interventions.
Collaborations
Throughout her career, Yukari Kanzaki has collaborated with esteemed colleagues, including Sumio Sugano and Tsuneo Saga. These partnerships have contributed to the success and impact of her research in the field.
Conclusion
Yukari Kanzaki is a trailblazer in the development of monoclonal antibodies, with a focus on biomarkers that enhance the detection and diagnosis of critical medical conditions. Her innovative work at Fujifilm Corporation and her collaborations with other experts underscore her significant contributions to biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile